Recent news on Thalomid

Sales Surge Not Enough for Celgene  -  May 3, 2007
TheStreet.comCelgene's other big medication, Thalomid, had sales of $106 million. Both Thalomid and Revlimid are used in treating the blood disease multiple myeloma.

EntreMed Reports First Quarter 2007 Financial Results  -  May 9, 2007
PharmaLive.com (press release),...variations in actual sales of Thalomid(R), risks associated with the integration of Miikana and its product candidates; the early-stage products under

Royalty Pharma Acquires a Portion of New York University's Royalty ...  -  May 4, 2007
PR Newswire (press release),Amgen's Neupogen(R) and Neulasta(R), Genentech's Rituxan(R), Gilead's Emtriva(R), Truvada(R) and Atripla(R), and Celgene's Thalomid(R).

Celgene triples earnings from year-ago  -  May 3, 2007
Newark Star Ledger,Revlimid is a safer, more potent version of Thalomid, a once-notorious morning sickness drug called thalidomide that was banned in the 1960s.

Spending on biotech drug prescriptions rising  -  26 Apr 2007
Scientific American...s cancer drug Thalomid. Express Scripts is one of three big companies that buy pharmaceuticals for US employers and health plans.

Royalty Pharma and InNexus Biotechnology Announce Agreement ...  -  26 Apr 2007
Genetic Engineering News (press release),Amgen's Neupogen(R) and Neulasta(R), Genentech's Rituxan(R), Gilead's Emtriva(R), Truvada(R) and Atripla(R), and Celgene's Thalomid(R).

Royalty Pharma and InNexus Biotechnology Announce Agreement ...  -  26 Apr 2007
Business Wire (press release),...including Abbott’s Humira®, Amgen’s Neupogen® and Neulasta®, Genentech’s Rituxan®, Gilead’s Emtriva®, Truvada® and Atripla®, and Celgene’s Thalomid®.

Velcade®, Alkeran®, Prednisone, and Thalomid® Effecive for ...  -  Mar 28, 2007
Cancer Consultants (press release),...conducted a clinical trial to evaluate VMPT (Velcade, Alkeran, Thalomid, and prednisone) in the treatment of 30 patients with relapsed multiple myeloma.

New Life-extending Drugs Drive Revenues in the US Multiple Myeloma ...  -  Apr 17, 2007
Newswire Today (press release),Particularly at the forefront of modern day multiple myeloma therapy are Thalomid, Revlimid, and Velcade—all fostering an unprecedented growth in the US

Celgene Says Survival Edge Found in Revlimid Study  -  Apr 4, 2007
Reuters.uk,Revlimid is a successor to Celgene's drug Thalomid, currently the leading treatment for multiple myeloma. Thalomid plus dexamethasone is typically the first

Zacks Analyst Blog Highlights: DR Horton, Lennar, Cost Plus and ...  -  Apr 11, 2007
Business Wire (press release),Its leading products are Thalomid (thalidomide) and Revlimid. Thalomid is an immunomodulatory agent with multiple-use potential.

Celgene stock rises amid drug trial data speculation  -  Apr 3, 2007
ReutersRevlimid is a successor to Celgene's drug Thalomid, currently the leading treatment for multiple myeloma. Revlimid is approved to treat patients with

EntreMed Presents Preclinical Data For MKC-1 In Hematological Cancers  -  Apr 20, 2007
Medical News Today (press release),...variations in actual sales of Thalomid(R), risks associated with the integration of Miikana and its product candidates; the early-stage products under

The Multiple Myeloma Research Consortium And Nereus ...  -  Apr 17, 2007
Medical News Today (press release),...who are resistant to Velcade, steroid therapy, Thalomid(R) (thalidomide, Celgene Corporation) and Revlimid(R) (lenalidomide, Celgene Corporation).

Lower doses of dexamethasone for multiple myeloma recommended  -  Apr 5, 2007
News-Medical.net,The findings are expected to prompt review of the dexamethasone dose when paired with other medications used in myeloma such as THALOMID(R), and discussions

The International Myeloma Foundation Says Recommendation for ...  -  Mar 30, 2007
Drug Newswire (press release),When approved it will join the other novel therapies including Thalomid (thalidomide) also from Celgene and distributed by Pharmion in Europe,

Celgene shares give back Friday's gains  -  27 Mar 2007
BusinessWeekHe also cited the company's prospects with cancer drug Thalomid as another positive factor for the company. The drug could turn out to have uses beyond

EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds  -  27 Mar 2007
PR Newswire (press release),...variations in actual sales of Thalomid(R), risks associated with the integration of Miikana and its product candidates; the early-stage products under

Velcade®, Alkeran®, Prednisone and Thalomid® Effecive for Relapsed ...  -  Mar 23, 2007
Cancer Consultants (press release),Thalomid containing regimens are now the most commonly used induction regimens for the initial treatment of newly diagnosed patients with multiple myeloma.

Velcade® Safe and Effective for Patients with Multiple Myeloma and ...  -  Mar 15, 2007
Cancer Consultants (press release),Only 2 patients received Velcade alone with the remainder receiving Velcade combined with dexamethasone, dexamethasone and Thalomid, Doxil and Thalomid or

CONSUMER WATCH: Patients can get help with pricey meds  -  Mar 10, 2007
Richmond Times Dispatch,A spokesman for Thalomid's maker, Celgene Corp. in Summit, NJ, said "the drug itself doesn't cost that much" to make. The price reflects the drug's

Velcade® Safe and Effective for Patients with Multiple Myeloma and ...  -  Mar 14, 2007
Cancer Consultants (press release),Two patients were treated with Velcade alone, while the others were treated with Velcade combined with dexamethasone, dexamethasone and Thalomid®,

Celgene's thalidomide-derived Revlimid gets European nod  -  Mar 26, 2007
Pharma Times (subscription),The agency gave the green light to Celgene's Thalomid (thalidomide) as a first-line treatment for the disease last May. The CHMP also gave verdicts on drugs

Needed From the FDA: Not Perfection, Just Consistency  -  Mar 8, 2007
TCS Daily,Other products subject to such regimes include Accutane, used to treat severe recalcitrant nodular acne; and Thalomid, for multiple myeloma and the

Pharmion Seeks European Thalidomid OK  -  Mar 1, 2007
Forbes,...(nasdaq: CELG - news - people ), which markets it in the United States as Thalomid. The company said the European Medicines Agency will review the drug for

Pharmion seeks European Thalidomid OK  -  Mar 1, 2007
BusinessWeekPharmion licensed rights to sell the drug in several companies from Celgene Corp., which markets it in the United States as Thalomid.

The International Myeloma Foundation Says Recommendation For ...  -  Mar 24, 2007
Medical News Today (press release),When approved it will join the other novel therapies including Thalomid (thalidomide) also from Celgene and distributed by Pharmion in Europe,

Senior R&D Management Promotions at EntreMed Support Current and ...  -  Mar 23, 2007
PharmaLive.com (press release),...variations in actual sales of Thalomid(R), risks associated with the integration of Miikana and its product candidates; the early-stage products under

EMEA Accepts for Review Thalidomide Pharmion(R) Marketing ...  -  Mar 23, 2007
Drug Newswire (press release),In May 2006, Thalomid(R) (thalidomide) was approved by the US Food and Drug Administration (FDA) in combination with dexamethasone for the treatment of

From the analyst's couch: Multiple myeloma therapies  -  Mar 2, 2007
Nature.com (subscription),In May 2006, thalidomide (Thalomid; Celgene), an oral drug that has anti-angiogenic and immunomodulatory properties, became the first therapy approved by

Sector Wrap: Biotechnology  -  Feb 27, 2007
Forbes,Nonetheless, the maker of bone marrow cancer treatment Thalomid and the blood disease treatment Revlimid shows a 48.8 percent gain over the past 52 weeks.

Market Report -- Short Stories (CELG)  -  Feb 21, 2007
MSN MoneyThe firm believes the co's success in marketing and developing Thalomid should aid in the adoption of Revlimid. Briefing.com is the leading Internet

Celgene Mints the Green Stuff  -  Feb 6, 2007
Motley FoolAn outcome from the litigation over the Thalomid patents is still years away at the earliest, since Celgene automatically gets a 30-month stay of FDA action

Earnings Preview: Celgene  -  Jan 31, 2007
Houston Chronicle,The year ended with Celgene facing a patent dispute by Barr Pharmaceuticals Inc., which plans to make a generic version of the drug Thalomid, which has been

Celgene Q4 2006 Earnings Call Transcript  -  Feb 1, 2007
Seeking Alpha,THALOMID net product sales for the full year also outpaced expectations achieving $433 million compared to $388 million in 2005.

Celgene Reported Exceptional Operating Performance Driven by ...  -  Feb 2, 2007
Drug Newswire (press release),The increase in total revenue was driven by REVLIMID net sales of $123.8 million, and THALOMID(R) net sales of $110.2 million. ALKERAN(R) net sales for the

New Jersey business briefs  -  Feb 2, 2007
NorthJersey.com,...s fourth-quarter profit rose more than fivefold on higher sales of the blood cancer drugs Revlimid and Thalomid. Net income increased to $22.9 million,

Celgene Looks Stellar: Fool by Numbers  -  Feb 2, 2007
Motley FoolRevenues increased by a drastic 84%, driven by an increase in sales of Revlimid and Thalomid and partially offset by a decrease in sales of Alkeran.

Celgene Sales Drive Solid Quarter  -  Feb 1, 2007
TheStreet.comRevlimid sales grew 22% quarter over quarter, although growth in Thalomid was just 1.7% from the third quarter and 4.1% year over year.

Celgene 4Q Profit Up Sixfold on Sales  -  Feb 1, 2007
Forbes,Revenue rose 84 percent to $275 million from $149.3 million last year, driven by sales of the cancer drugs Thalomid and Revlimid.

Celgene Expects Profit to Double in 2007  -  Feb 1, 2007
Forbes,Sales of the cancer drugs Thalomid and Revlimid accounted for $433 million and $320.6 million in 2006 revenue, respectively.

Celgene fourth-quarter profit $22.9 mln  -  Feb 1, 2007
MarketWatch...pharmaceutical company said total revenue rose 84% to $275 million from $149.3 million in the year-ago period, helped by sales of Revlimid and Thalomid.

Can Celgene Keep Momentum Going?  -  Jan 31, 2007
TheStreet.comBarr Pharmaceuticals' (BRL - Cramer's Take - Stockpickr) recent FDA filing seeking an abbreviated new drug application for a generic version of Thalomid.

Celgene Reported Exceptional Operating Performance Driven by ...  -  Feb 1, 2007
Yahoo! News (press release)The increase in total revenue was driven by REVLIMID net sales of $123.8 million, and THALOMID® net sales of $110.2 million. ALKERAN® net sales for the

Leading Experts To Conduct Los Angeles Seminar On Myeloma ...  -  Feb 22, 2007
Medical News Today (press release),..."We are using new drugs -- THALOMID, REVLIMID and VELCADE -- that attack not just the cancer cell, but the environment in which it lives," said Dr. Durie,

Investing in Stem Cell Stocks: Growth Industry of the Future?  -  Feb 21, 2007
Seeking Alpha,Their primary product includes THALOMID, for the treatment of erythema nodosum leprosum. Last year, the company received patent on placental stem cell

The Biotech Academy Awards  -  Feb 16, 2007
Motley FoolCelgene also expanded the marketing labels for both Thalomid and Revlimid, which should drive sales growth for years to come.

Barr Confirms Generic Thalomid(R) Capsule, 50 mg and 100 mg ...  -  Dec 27, 2006
Drug Newswire (press release),Barr filed an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for a generic version of Thalomid Capsules with the FDA in

Barr seeks generic Thalomid approval  -  Dec 26, 2006
BusinessWeek...s Thalomid drug in 50 milligram and 100 milligram doses. Celgene markets thalidomide to treat erythema nodosum leprosum, a condition in patients with

Barr Seeks Generic Thalomid Approval  -  Dec 26, 2006
Forbes,...s Thalomid drug in 50 milligram and 100 milligram doses. Celgene (nasdaq: CELG - news - people ) markets thalidomide to treat erythema nodosum leprosum,

Celgene (CELG) Said ANDA Filing for Generic THALOMID Filed with FDA  -  Dec 26, 2006
StreetInsider.com (subscription),Celgene markets thalidomide under the brand name THALOMID and has approval to market as a treatment in combination with dexamethasone for newly diagnosed

(PRN) - Barr Confirms Generic Thalomid(R) Capsule, 50 mg and 100 ...  -  Dec 26, 2006
Bolsamania.com,...(PRN) - Wrap Up the Holiday Season by Donating Old Wireless Phones to Verizon Wireless' HopeLine(R) Program ... [+]. (PRN) - Barcelo Hotels & Resorts

Celgene Anticipates FY06 Adj. EPS To Triple; Guides FY07 EPS Below ...  -  Jan 8, 2007
Trading Markets,Net product sales for Revlimid reached a range of $315-$320 million, while net product sales of Thalomid reached a range of $425-$430 million.

Celgene Corporation Reviews 2006 Achievements and Announces 2007 ...  -  Jan 8, 2007
PR Newswire (press release),The successful growth of product revenue continues to reflect the positive reception by hematologist/oncologists for REVLIMID and THALOMID based on the

Analysis: Analysts cautious on Celgene  -  Jan 9, 2007
Science Daily (press release)Thalomid 2006 sales, coming in at $425 million to $430 million, are in line with consensus. Revlimid's growth will probably cut into sales of Thalomid in

Pharma Sector: Few Newsmakers Of The Week - Eli Lilly, Bristol ...  -  Dec 29, 2006
Trading Markets,The most feared drug of the twentieth century - Celgene's Thalomid, which was banned worldwide in 1962, appears to be gaining respectability.

Biogen Idec Initiates Phase III Clinical Program and Genzyme ...  -  Jan 10, 2007
Financial News USA (press release),...record results towards maximizing the commercial potential of REVLIMID and THALOMID for the treatment of patients with certain blood cancers in the US

Celgene Slides on Conservative Outlook  -  Jan 9, 2007
Forbes,The company derives revenue from its two cancer drugs Revlimid, with expected sales of $425 million to $430 million this year, and Thalomid,

Celgene Disappoints Street  -  Jan 9, 2007
Forbes,Celgene said sales of Revlimid reached a range of $315 million to $320 million, while Thalomid sales reached a range of $425 to $430.

Barr expands its bid to offer generic form of cancer drug  -  Dec 27, 2006
NorthJersey.com,Under federal law, if Celgene files suit within 45 days of the date Barr notified Celgene of its intention to challenge the Thalomid patent, the FDA cannot

Celgene "market outperform," target price reduced  -  Jan 10, 2007
newratings.com...reported its preliminary 2006 top-line short of the estimates and the consensus, primarily due to lower-than-anticipated sales of Revlimid and Thalomid.

Celgene 2007 Outlook Misses Street View  -  Jan 9, 2007
Forbes,The company also forecast annual revenue of $890 million, up 60 percent year-over-year, on strong sales of its Revlimid and Thalomid drugs.

Celgene View Dims  -  Jan 8, 2007
TheStreet.comThalomid sales ranged from $425 million to $430 million. Adjusted earnings per share nearly tripled in 2006. Earlier this week, the Summit,

Celgene sees 2007 EPS below Street view  -  Jan 8, 2007
ReutersCelgene said sales of Revlimid reached $315 million to $320 million for 2006, while Thalomid sales reached $425 million to $430 million.

The New America  -  Dec 28, 2006
Investor's Business Daily (subscription)The company is riding high on sales from Revlimid, a follow-up to its popular Thalomid drug. Revlimid has grown as a treatment for a blood and bone marrow

Celgene "market outperform"  -  Jan 3, 2007
newratings.comIn a research note published this morning, the analysts mention that the company has reported the November sales of its Thalomid drug significantly short of

New Jersey business briefs  -  Jan 3, 2007
NorthJersey.com,SUMMIT -- Celgene Corp., maker of the leprosy and blood cancer drug Thalomid, named Chief Executive Officer Sol Barer to succeed John W. Johnson as chairman

The Year in Review: Celgene Corp.  -  Dec 28, 2006
Forbes,Thalidomide, marketed as Thalomid, was banned in 1962 because it was found to cause birth defects. But in 1998 the FDA approved the drug to treat leprosy,

Celgene: Barr seeks FDA OK for generic Thalidomide  -  Dec 26, 2006
MarketWatchCelgene, a Summit, NJ, pharmaceutical company that markets thalidomide under the brand name Thalomid, said Tuesday it plans to file a patent-infringement

Garden State Business Briefs  -  Dec 26, 2006
Newark Star Ledger,Barr Pharmaceuticals' Barr Labs unit said yesterday it applied for Food and Drug Administration approval for a generic version of Celgene's Thalomid drug in

Celgene Notified of ANDA Filing for Thalidomide  -  Dec 26, 2006
PR Newswire (press release),Celgene Corporation markets thalidomide under the brand name THALOMID(R) and has approval to market as a treatment in combination with dexamethasone for

Celgene Notified of ANDA Filing for Thalidomide  -  Dec 26, 2006
Yahoo! News (press release)Celgene Corporation markets thalidomide under the brand name THALOMID® and has approval to market as a treatment in combination with dexamethasone for newly

Barr confirms seeking FDA approval for more thalidomide generics  -  Dec 27, 2006
Therapeutics Daily (subscription) (press release),Celgene sells thalidomide under the brand name Thalomid for certain cancers and complications of leprosy. (Reporting by John Tilak in Bangalore)

Barr expands its bid to offer generic form of cancer drug  -  Dec 27, 2006
Therapeutics Daily (subscription) (press release),Woodcliff Lake-based Barr first announced plans to make the drug Thalomid in 200-milligram capsules on Dec. 13. The company said it will now amend that

Barr confirms seeking FDA approval for more thalidomide generics  -  Dec 26, 2006
ReutersCelgene sells thalidomide under the brand name Thalomid for certain cancers and complications of leprosy. (Reporting by John Tilak in Bangalore)

Celgene Receives Notice of Barr Filing  -  Dec 26, 2006
Forbes,...(nasdaq: CELG - news - people ) markets thalidomide as a cancer treatment under the brand name Thalomid. But the company says it also has approval from the

Celgene Receives Notice of Barr Filing  -  Dec 26, 2006
Houston Chronicle,Celgene Corp. markets thalidomide as a cancer treatment under the brand name Thalomid. But the company says it also has approval from the Food and Drug

Celgene says Barr seeks more thalidomide generics  -  Dec 26, 2006
ReutersCelgene sells thalidomide under the brand name Thalomid for certain cancers and complications of leprosy. Earlier this month, Celgene said Barr had filed an

Celgene receives notice of Barr filing  -  Dec 26, 2006
FinanzNachrichten.de,...(Nachrichten/Aktienkurs) markets thalidomide as a cancer treatment under the brand name Thalomid. But the company says it also has approval from the Food

Market Report -- In Play (CELG)  -  Dec 26, 2006
MSN MoneyCELG markets thalidomide under the brand name Thalomid and has approval to market as a treatment in combination with dexamethasone for newly diagnosed

NCCN Updates Antiemesis Guidelines  -  Jan 8, 2007
PharmaLive.com (press release),...sunitinib (Sutent, Pfizer), thalidomide (Thalomid, Celgene), and trastuzumab (Herceptin, Genentech) are all now considered to have minimal emetic risk.

Merrill Lynch Raises Its Price Target on Celgene (CELG) to $73  -  Jan 4, 2007
StreetInsider.com (subscription),Thalomid sales are also holding up very well. Assuming some off-label use of Revlimid in relapsed/refractory CLL and ultimately label expansion,

The Year in Review: Barr Shops in Europe  -  Dec 28, 2006
Forbes,Barr, which has been on the S&P 500 Index since February, closed the year by asking the FDA to approve a generic version of Celgene Corp's Thalomid,

MedImmune In-Licenses Novel Inflammatory Disease Target and The ...  -  Dec 29, 2006
Financial News USA (press release),Thalidomide, marketed as Thalomid, was banned in 1962 because it was found to cause birth defects. Celgene shares have surged since the beginning of the

(PRN) - Following Is a Test Release ... [+]  -  Dec 26, 2006
Bolsamania.com,...(PRN) - Comic Book Heroes Brighten Eid Holiday for Youth of Palestine, Lebanon and Iraq ... [+]. (PRN) - Barr Confirms Generic Thalomid(R) Capsule,

(PRN) - Following Is a Test Release ... [+]  -  Dec 26, 2006
Bolsamania.com,...(PRN) - Barr Confirms Generic Thalomid(R) Capsule, 50 mg and 100 mg Application ... [+]. (PRN) - MIB Life Index Reports US Life Insurance Activity Declines

Celgene Plans Suit After Notification Barr Files ANDA for ...  -  Dec 26, 2006
Therapeutics Daily (subscription) (press release),Celgene Corporation markets thalidomide unde r the brand name THALOMID and has approval to market as a treatment in combination with dexamethasone for newly

"Bank On A Cure" Researchers Identify Pathways Mediating Myeloma ...  -  Dec 25, 2006
Medical News Today (press release),Thalidomide (Thalomid® from the Celgene Corporation in the US) is a widely prescribed treatment for multiple myeloma that has been shown to extend and

Novel Orally-Active Kinase Inhibitor Induces Tumor Regression In ...  -  Dec 24, 2006
Medical News Today (press release),...variations in actual sales of Thalomid(R), risks associated with development of product candidates; the early-stage products under development;

EntreMed's Panzem(R) Demonstrates Antitumor Activity in Brain ...  -  Dec 21, 2006
Yahoo! News (press release)...variations in actual sales of Thalomid®, risks associated with development of product candidates; the early-stage products under development;

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional